Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC to Present Biomarker Data for Cancer Drug Resminostat at EHA

Published: Monday, June 18, 2012
Last Updated: Monday, June 18, 2012
Bookmark and Share
Data from Phase II SAPHIRE trial in Hodgkin’s lymphoma presented at EHA meeting in Amsterdam.

4SC AG has presented data of a set of biomarkers and their possible utility for stratification of patient populations analyzed in the clinical Phase II SAPHIRE study with its anti-cancer compound resminostat in patients with relapsed/refractory Hodgkin’s lymphoma (HL) at the 17th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands from 14-17 June 2012.

The poster will be presented at the Hogdin's lymphoma session, Friday, 15 June 2012, from 5:45-7:00 pm (CEDT) and will report new data on the correlation of resminostat plasma levels and its pharmacodynamic effect on a set of biomarkers, including HDAC enzyme inhibition and the level of critical plasma proteins such as TARC.

Furthermore, based on expression analysis of a set of marker genes regulated by resminostat, the identification and potential of certain gene expressions to serve as either additional pharmacodynamic markers or to qualify as biomarkers for patient stratification or prediction of clinical response to resminostat will be discussed.

Dr. Bernd Hentsch, Chief Development Officer, commented: “Our biomarker analysis program has resulted in the identification of novel gene expressions that may serve as tools for the identification of those HL patients who could have a higher chance of obtaining a clinical benefit from resminostat treatment. This approach now opens the opportunity to target resminostat therapy more effectively to this patient group. Furthermore, we are applying this biomarker program to all our target indications, including HCC and CRC, in order to also explore possible stratification opportunities for those patients.”

The final efficacy data of the SAPHIRE study evaluating resminostat monotherapy in relapsed and/or refractory Hodgin's lymphoma patients had been presented at last year’s ASH conference.

The study met the primary efficacy endpoint with an overall response rate (ORR) of 35.3% and a clinical benefit in 55.9% of these heavily pretreated patients together with a very clean safety and tolerability profile.

The open-label, single-arm, international study evaluated safety, pharmacokinetics, biomarkers, and efficacy of resminostat monotherapy treatment in 34 patients with advanced HL.

Patients enrolled in the trial had either relapsed after high dose chemotherapy and/or autologous stem cell transplantation (ASCT) or had become refractory to treatment, and had on average received 6 prior treatments.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Discovery Collaborates with Heidelberg University Hospital
The two-year R&D project is aimed at delivering a lead compound that can be brought to clinical development with the help of potential partners.
Friday, March 21, 2014
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
4SC Announces Positive Interim Results from Clinical Phase I/II SHORE Study
Phase II part of study planned to start soon in 2013.
Thursday, December 13, 2012
4SC's Partner Yakult Honsha Starts Clinical Development with Cancer Compound Resminostat in Japan
The Phase I study will assess safety of resminostat in Japanese patients, which is a prerequisite of the drug's further late-stage clinical development in Japan.
Monday, May 21, 2012
4SC Announces Treatment of First Patient in Phase I TOPAS Study with the Selective HDAC Inhibitor 4SC-202
The study evaluate the safety, pharmacokinetics and clinical efficacy of 4SC-202 in patients with advanced hematological indications, including AML, ALL, CLL, MM, MDS and lymphomas.
Thursday, April 14, 2011
4SC Announces First Patient Dosed in Phase I/II SHORE Study with Resminostat
The first patient dosed in the study with resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
Friday, January 21, 2011
4SC Announces First-in-Man Phase I Results for 4SC-203
The company announces successful completion of Phase I study in healthy volunteers with the multi-target kinase inhibitor 4SC-203.
Sunday, January 09, 2011
4SC Announces Start of Dosing in First-in-Man Phase I Study with 4SC-203
This study investigates activity of 4SC-203 in 50 volunteers and comprises seven treatment cohorts.
Friday, January 22, 2010
4SC Announces Clinical Advancements in its Oncology Pipeline
The company, focused on autoimmune and cancer indications, initiates three new clinical trials for its oncology franchise.
Thursday, December 24, 2009
Scientific News
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!